Purdue OxyContin Abuse-Resistant Pill Will Need 4-5 Years To Complete Trials
Executive Summary
Purdue expects clinical trials of abuse-resistant OxyContin formulated with the opioid antagonist naltrexone will take four to five years to complete, after determining that a combination product with naloxone will likely not be feasible
You may also be interested in...
Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval
The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch
Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval
The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch
Purdue OxyContin Marketing Strategy To Be Topic Of GAO Investigation
Purdue Pharma's marketing strategies for OxyContin will be the topic of a Government Accounting Office report requested by House Appropriations/Commerce, Justice, State & Judiciary Subcommittee Chairman Frank Wolf (R-Va.)